Price Alert

Radiopharm Theranostics L... (RADX)

NASDAQ: RADX · Real-Time Price · USD

4.78

-0.23 (-4.69%)

At close: Aug 15, 2025, 2:14 PM

5.12

7.11%

After-hours: Aug 15, 2025, 05:49 PM EDT

Radiopharm Theranostics Statistics

Share Statistics

Radiopharm Theranostics has n/a shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Institutions (%)	n/a
Shares Floating	n/a
Failed to Deliver (FTD) Shares	2,000
FTD / Avg. Volume	9.44%

Short Selling Information

The latest short interest is 15.12K, so 0% of the outstanding shares have been sold short.

Short Interest	15.12K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is -0.71 and the forward PE ratio is -1.03. Radiopharm Theranostics's PEG ratio is -0.07.

PE Ratio	-0.71
Forward PE	-1.03
PS Ratio	114.19
Forward PS	26.6
PB Ratio	1.22
P/FCF Ratio	-1.49
PEG Ratio	-0.07

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Radiopharm Theranostics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.3, with a Debt / Equity ratio of 0.

Current Ratio	1.3
Quick Ratio	1.3
Debt / Equity	0
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-56.96

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	undefined
Asset Turnover	0
Inventory Turnover	n/a

Taxes

Income Tax	96.36K
Effective Tax Rate	-0.2%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.81, so Radiopharm Theranostics's price volatility has been higher than the market average.

Beta	0.81
52-Week Price Change	n/a
50-Day Moving Average	4.67
200-Day Moving Average	n/a
Relative Strength Index (RSI)	49.54
Average Volume (20 Days)	21,182

Income Statement

In the last 12 months, Radiopharm Theranostics had revenue of 299.23K and earned -47.95M in profits. Earnings per share was -37.22.

Revenue	299.23K
Gross Profit	299.23K
Operating Income	-36.62M
Net Income	-47.95M
EBITDA	-44.08M
EBIT	-47.21M
Earnings Per Share (EPS)	-37.22

Full Income Statement

Balance Sheet

The company has 18.58M in cash and 0 in debt, giving a net cash position of 18.58M.

Cash & Cash Equivalents	18.58M
Total Debt	n/a
Net Cash	n/a
Retained Earnings	-111.34M
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	-22.98M
FCF Per Share	-17.84

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -12238.44% and -16024.28%.

Gross Margin	100%
Operating Margin	-12238.44%
Pretax Margin	-15992.07%
Profit Margin	-16024.28%
EBITDA Margin	-14732.44%
EBIT Margin	-12238.44%
FCF Margin	-7678.4%

Dividends & Yields

RADX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RADX is $15, which is 234.1% higher than the current price. The consensus rating is "Buy".

Price Target	$15
Price Target Difference	234.1%
Analyst Consensus	Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a